ROS-Sensitive Prodrugs for Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prodrug strategies lack specificity in targeting diseases and indications due to non-specific esterase catalysis, which affects the efficient in-vivo removal of chemical modifications and localization of bioactive molecules.
Innovation Solution
Development of prodrugs sensitive to reactive oxygen species (ROS) with specific chemical modifications that allow targeted activation and release of the drug moiety in ROS-rich environments, such as those found in cancer, neurodegenerative diseases, inflammation, fibrosis, and cardiovascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If esterase catalysis is used for prodrug activation, then in-vivo removal of chemical modification is facilitated, but specificity to disease and target is lost due to ubiquitous esterase activity
Solution Approach 1:
The patent changes the chemical parameter of the prodrug from ester bonds (hydrolyzed by ubiquitous esterases) to ROS-sensitive bonds (cleaved by reactive oxygen species). This parameter change allows the prodrug to respond specifically to the elevated ROS levels in disease states (cancer, inflammation, neurodegenerative diseases) rather than being activated by constitutive esterase activity, thereby achieving both efficient in-vivo removal and disease-specific targeting
Solution Approach 2:
The patent applies local quality by designing the prodrug to be activated only in locations with high ROS concentration (disease sites) rather than throughout the entire body. The ROS-sensitive chemical bonds remain stable in normal tissues with low ROS levels but are selectively cleaved in disease environments where ROS is elevated, creating spatial specificity without requiring complex delivery systems
2Reliability
If prodrugs are designed for targeted activation, then therapeutic efficacy is enhanced, but systemic side effects may occur due to non-specific activation
Solution Approach 1:
The patent changes the activation parameter from enzyme-dependent (esterase) to ROS-dependent chemical cleavage. Since ROS levels are naturally elevated in disease states (cancer cells, inflamed tissues, neurodegenerative conditions) but low in healthy tissues, this parameter change ensures the prodrug activates preferentially at the disease site, enhancing therapeutic efficacy while minimizing systemic side effects through passive biochemical discrimination rather than active targeting mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ROS-sensitive prodrugs enable targeted and efficient activation within specific disease environments, enhancing therapeutic efficacy while minimizing systemic side effects.
Implementation Method 1
ROS-sensitive chemical modifications
Data Source
AI summary
Provided herein are ROS-sensitive prodrug compositions and methods of treating ROS-associated diseases by administering the ROS-sensitive prodrug compositions.